Data capture is no longer the bottleneck, and whether the lag between a signal and a decision shrinks depends on signal design, AI governance, and vendor orchestration.
|Webcasts|September 30, 2021
Empowered Trial Selection with Weighting and Prioritization Tools
Author(s)Cytel
Thursday, September 30, 2021 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST Give yourself a competitive edge by learning how the world’s leading designer of innovative clinical trials can help you integrate elements of economic theory to your clinical trial design. Optimize sample size, speed, and power by exploring a broader array of designs and quickly identifying those that meet your objectives.
Register Free:
Event Overview:
The current state of innovative clinical trial design has led many to propose a better integration of clinical strategy with economic principles, to help optimize trial design. This webinar will reveal how trial sponsors can quickly explore millions of trial designs through advanced simulation methods, then use weighting and prioritization techniques to find the optimal trial for a given context. The webinar will consider how different performance characteristics like the length of a clinical trial or the sample size, can be weighed against each other through clear quantification of tradeoffs. Then it will reveal how to begin building trial designs that are certain to meet these criteria.
Key Learning Objectives:
- Learn how to integrate basic economic principles like Pareto optimization, scoring functions and convex hulls into your clinical trial design strategy
- Learn how different trial performance characteristics like length of trial, sample size and power can be weighed against each other in a clear, quantifiable manner
- Learn how to reveal the optimal trial design for a particular clinical or market context within days rather than months
Who Should Attend:
- Biopharmaceuticals
- Biotechnology
- Drug Development
- Pharmaceutical
- R&D
Speaker
Yannis Jemiai
Chief Scientific Officer
Cytel
Register Free:
Related to this article
In this Q&A, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, discusses what changes when AI is embedded across protocol strategy, data infrastructure, and workflow tools at once, where governance frameworks tend to fall short, and why CROs must orchestrate AI ecosystems rather than simply aggregate them.
In today’s ACT Brief, we examine what policy changes would help community and rural institutions join research, how Walmart is expanding clinical trial centers into three more states, and how FDA approved Ilumya for adults with active psoriatic arthritis.
The planned sites in Livonia, Las Vegas, and San Antonio would expand a partnership that places clinical research and health screenings inside Walmart stores.
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.
In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option, and how closing that gap could improve outcomes and lower long-term costs.
Trending on Applied Clinical Trials Online
1
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
2
What Needs to Happen Beyond the Clinical Trial Modernization Act
3
From Signal to Action: Why Faster Trial Data Isn’t Producing Faster Decisions
4
Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas
5